Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

这项开创性临床试验10月31日发表于《美国人类遗传学杂志》。该研究将采用CRISPR-Cas9基因编辑技术的一个分支——碱基编辑，它允许科学家对DNA序列进行精确的“单字母”修改。研究计划于明年启动，此前组织者已花费数月时间与美国监管机构谈判，旨在简化基因编辑疗法进入试验前通常必须经过的复杂程序。

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

Cathie Wood's ARK Invest bought $17M in CRISPR and Beam gene-editing stocks while selling Teradyne, Roku, and SoFi shares on ...

When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...

This Collection supports and amplifies research related to SDG 2 - Zero hunger, SDG-3 (Good health and well-being), SDG-12 (Responsible consumption and production), and SDG-13 (Climate Action). CRISPR ...